Lee Danner & Bass Inc. increased its stake in Amgen Inc. (NASDAQ:AMGN) by 0.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 31,594 shares of the medical research company’s stock after buying an additional 19 shares during the period. Lee Danner & Bass Inc.’s holdings in Amgen were worth $5,184,000 at the end of the most recent quarter.
Other hedge funds also recently bought and sold shares of the company. Alpha Omega Wealth Management LLC increased its stake in Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock valued at $103,000 after buying an additional 100 shares during the last quarter. Jackson Grant Investment Advisers Inc. increased its stake in Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after buying an additional 4 shares during the last quarter. Nelson Roberts Investment Advisors LLC bought a new stake in Amgen during the first quarter valued at about $121,000. Signature Estate & Investment Advisors LLC increased its stake in Amgen by 13.6% in the first quarter. Signature Estate & Investment Advisors LLC now owns 794 shares of the medical research company’s stock valued at $130,000 after buying an additional 95 shares during the last quarter. Finally, Cable Hill Partners LLC increased its stake in Amgen by 2.7% in the first quarter. Cable Hill Partners LLC now owns 982 shares of the medical research company’s stock valued at $161,000 after buying an additional 26 shares during the last quarter. Hedge funds and other institutional investors own 79.12% of the company’s stock.
Shares of Amgen Inc. (NASDAQ AMGN) traded up 1.276% during midday trading on Tuesday, reaching $170.305. The company’s stock had a trading volume of 407,750 shares. The firm has a market cap of $124.27 billion, a price-to-earnings ratio of 15.512 and a beta of 1.35. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $184.21. The company has a 50-day moving average price of $173.92 and a 200-day moving average price of $168.25.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.84 EPS. Equities analysts expect that Amgen Inc. will post $12.57 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Thursday, August 17th will be given a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a dividend yield of 2.74%. The ex-dividend date is Tuesday, August 15th. Amgen’s dividend payout ratio (DPR) is 41.93%.
Several analysts have issued reports on AMGN shares. Oppenheimer Holdings, Inc. set a $189.00 price objective on Amgen and gave the stock a “buy” rating in a report on Tuesday, May 9th. Mizuho set a $195.00 price objective on Amgen and gave the stock a “buy” rating in a report on Saturday, May 6th. Cowen and Company restated a “buy” rating and set a $209.00 price objective on shares of Amgen in a report on Thursday, April 27th. BMO Capital Markets restated a “buy” rating and set a $198.00 price objective (down previously from $200.00) on shares of Amgen in a report on Monday, May 22nd. Finally, ValuEngine upgraded Amgen from a “hold” rating to a “buy” rating in a report on Thursday, July 6th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $186.04.
In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of the business’s stock in a transaction that occurred on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the transaction, the senior vice president now owns 24,214 shares of the company’s stock, valued at approximately $3,738,641.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.20% of the stock is owned by insiders.
About Amgen
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
